BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Aprepitant

A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.

297+ PubMed studies analyzed · 72 RCTs · Evidence Score: 57.2

Research Domains

Aprepitant has been studied across 18 research domains including 🔬 Oncology, 🌤️ Mood & Depression, 🫁 Liver & Detox, 🔬 Inflammation, 💊 Pain. The primary research focus is 🔬 Oncology with 31% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Aprepitant, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Melphalan
21 shared targets
Oxymetholone
17 shared targets
Lumefantrine
14 shared targets
17
18 shared targets
Polidocanol
15 shared targets
Testosterone
16 shared targets
Betamethasone
13 shared targets
Retinaldehyde
17 shared targets
Finasteride
13 shared targets
Beclomethasone
13 shared targets
Loading evidence profile...

This evidence profile for Aprepitant is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.